GlaxoSmithKline PLC ADR (GSK) - Total Assets
Based on the latest financial reports, GlaxoSmithKline PLC ADR (GSK) holds total assets worth $61.01 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See GSK net asset value for net asset value and shareholders' equity analysis.
GlaxoSmithKline PLC ADR - Total Assets Trend (1985–2025)
This chart illustrates how GlaxoSmithKline PLC ADR's total assets have evolved over time, based on quarterly financial data.
GlaxoSmithKline PLC ADR - Asset Composition Analysis
Current Asset Composition (December 2025)
GlaxoSmithKline PLC ADR's total assets of $61.01 Billion consist of 28.7% current assets and 71.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.6% |
| Accounts Receivable | $7.75 Billion | 12.7% |
| Inventory | $5.91 Billion | 9.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $16.72 Billion | 27.4% |
| Goodwill | $7.01 Billion | 11.5% |
Asset Composition Trend (1985–2025)
This chart illustrates how GlaxoSmithKline PLC ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see GSK market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GlaxoSmithKline PLC ADR's current assets represent 28.7% of total assets in 2025, a decrease from 67.7% in 1985.
- Cash Position: Cash and equivalents constituted 5.6% of total assets in 2025, up from 1.9% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 38.0% of total assets, an increase from 0.0% in 1985.
- Asset Diversification: The largest asset category is intangible assets at 27.4% of total assets.
GlaxoSmithKline PLC ADR Competitors by Total Assets
Key competitors of GlaxoSmithKline PLC ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.07 Billion |
|
Novartis AG
MX:NVSN
|
Mexico | MX$110.95 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $115.57 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$208.73 Billion |
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
China | CN¥13.11 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$1.83 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$112.48 Billion |
GlaxoSmithKline PLC ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.82 | 0.78 | 0.91 |
| Quick Ratio | 0.54 | 0.52 | 0.61 |
| Cash Ratio | 0.16 | 0.18 | 0.00 |
| Working Capital | $-3.87 Billion | $-4.70 Billion | $-2.42 Billion |
GlaxoSmithKline PLC ADR - Advanced Valuation Insights
This section examines the relationship between GlaxoSmithKline PLC ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.22 |
| Latest Market Cap to Assets Ratio | 1.82 |
| Asset Growth Rate (YoY) | 2.6% |
| Total Assets | $61.01 Billion |
| Market Capitalization | $111.15 Billion USD |
Valuation Analysis
Above Book Valuation: The market values GlaxoSmithKline PLC ADR's assets above their book value (1.82x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: GlaxoSmithKline PLC ADR's assets grew by 2.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for GlaxoSmithKline PLC ADR (1985–2025)
The table below shows the annual total assets of GlaxoSmithKline PLC ADR from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $61.01 Billion | +2.60% |
| 2024-12-31 | $59.46 Billion | -20.95% |
| 2023-12-31 | $75.22 Billion | +25.06% |
| 2022-12-31 | $60.15 Billion | -43.86% |
| 2021-12-31 | $107.14 Billion | -2.55% |
| 2020-12-31 | $109.95 Billion | +4.14% |
| 2019-12-31 | $105.57 Billion | +81.81% |
| 2018-12-31 | $58.07 Billion | +2.99% |
| 2017-12-31 | $56.38 Billion | -4.57% |
| 2016-12-31 | $59.08 Billion | +10.54% |
| 2015-12-31 | $53.45 Billion | +31.48% |
| 2014-12-31 | $40.65 Billion | -3.41% |
| 2013-12-31 | $42.09 Billion | +1.47% |
| 2012-12-31 | $41.48 Billion | +0.96% |
| 2011-12-31 | $41.08 Billion | -2.31% |
| 2010-12-31 | $42.05 Billion | -1.89% |
| 2009-12-31 | $42.86 Billion | +8.81% |
| 2008-12-31 | $39.39 Billion | +27.06% |
| 2007-12-31 | $31.00 Billion | +21.33% |
| 2006-12-31 | $25.55 Billion | -6.05% |
| 2005-12-31 | $27.20 Billion | +18.54% |
| 2004-12-31 | $22.94 Billion | -4.18% |
| 2003-12-31 | $23.94 Billion | +7.24% |
| 2002-12-31 | $22.33 Billion | +1.65% |
| 2001-12-31 | $21.97 Billion | +1.74% |
| 2000-12-31 | $21.59 Billion | +107.06% |
| 1999-12-31 | $10.43 Billion | +11.57% |
| 1998-12-31 | $9.35 Billion | +10.77% |
| 1997-12-31 | $8.44 Billion | +1.48% |
| 1996-12-31 | $8.31 Billion | -2.66% |
| 1995-12-31 | $8.54 Billion | +5.42% |
| 1994-12-31 | $8.10 Billion | +2.73% |
| 1993-12-31 | $7.89 Billion | +5.75% |
| 1992-12-31 | $7.46 Billion | +31.26% |
| 1991-12-31 | $5.68 Billion | -1.08% |
| 1990-12-31 | $5.74 Billion | +27.87% |
| 1989-12-31 | $4.49 Billion | +29.49% |
| 1988-12-31 | $3.47 Billion | +21.00% |
| 1987-12-31 | $2.87 Billion | +21.59% |
| 1986-12-31 | $2.36 Billion | +30.78% |
| 1985-12-31 | $1.80 Billion | -- |
About GlaxoSmithKline PLC ADR
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more